UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 13, 2010
Brainstorm
Cell Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
333-61610
|
20-8133057
|
||||
|
(State
or other jurisdiction of incorporation)
|
(Commission
File No.)
|
(IRS
Employer Identification No.)
|
|
110
East 59th
Street
|
|
|
New
York, New York
|
10022
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(212)
557-9000
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
(d) Election of
Director
On
December 13, 2010, the Board of Directors of BrainStorm Cell Therapeutics Inc.
(the “Company”) elected Alon Pinkas to the Board of Directors.
There are
no arrangements or understandings between Mr. Pinkas and any other persons
pursuant to which Mr. Pinkas was appointed as a director. There have been
no transactions and there are no currently proposed transactions to which the
Company or any of its subsidiaries was or is a party in which Mr. Pinkas
has a material interest, which are required to be disclosed under
Item 404(a) of Regulation S-K.
Mr.
Pinkas will receive equity compensation consistent with what is paid to the
other non-employee directors of the Company.
At this time, the committees of the Board of Directors to which Mr.
Pinkas will be named have not been determined.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
December
17, 2010
|
Brainstorm
Cell Therapeutics Inc.
|
||
|
By:
|
/s/ Chaim
Lebovits
|
||
|
Chaim
Lebovits
|
|||
|
President
|
|||